Preliminary study of anxiety symptoms, family dysfunction, and the brain-derived neurotrophic factor (BDNF) Val66Met genotype in offspring of parents with bipolar disorder

Park, Min Hyeon; Chang, Kiki; Hallmayer, Joachim; Howe, Meghan; Kim, Eun Joo; Hong, Seung Chul; Singh, Manpreet K.

doi:10.1016/j.jpsychires.2014.11.013

Cited by 21 publications

(24 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Duffy et al reported that the BDNF genotype significantly moderates the association between high-risk status for both gene expression and protein levels in BD offspring [88]. Correspondingly, anxiety symptoms were associated with the BDNF risk genotype only in BD offspring but not in healthy controls, and BD offspring with the val/val genotype showed higher anxiety symptoms than BD offspring with other genotypes [94]. …”

Section: Resultsmentioning

confidence: 99%

Neurobiology of Risk for Bipolar Disorder

Özerdem

Ceylan

Can

2016

Curr Treat Options Psych

View full text Add to dashboard Cite

Opinion statementBipolar disorder (BD) is a chronic mental illness which follows a relapsing and remitting course and requires lifetime treatment. The lack of biological markers for BD is a major difficulty in clinical practice. Exploring multiple endophenotypes to fit in multivariate genetic models for BD is an important element in the process of finding tools to facilitate early diagnosis, early intervention, prevention of new episodes, and follow-up of treatment response in BD. Reviewing of studies on neuroimaging, neurocognition, and biochemical parameters in populations with high genetic risk for the illness can yield an integrative perspective on the neurobiology of risk for BD. The most up-to-date data reveals consistent deficits in executive function, response inhibition, verbal memory/learning, verbal fluency, and processing speed in risk groups for BD. Functional magnetic resonance imaging (fMRI) studies report alterations in the activity of the inferior frontal gyrus, medial prefrontal cortex, and limbic areas, particularly in the amygdala in unaffected first-degree relatives (FDR) of BD compared to healthy controls. Risk groups for BD also present altered immune and neurochemical modulation. Despite inconsistencies, accumulating data reveals cognitive and imaging markers for risk and to a less extent resilience of BD. Findings on neural modulation markers are preliminary and require further studies. Although the knowledge on the neurobiology of risk for BD has been inadequate to provide benefits for clinical practice, further studies on structural and functional changes in the brain, neurocognitive functioning, and neurochemical modulation have a potential to reveal biomarkers for risk and resilience for BD. Multimodal, multicenter, population-based studies with large sample size allowing for homogeneous subgroup analyses will immensely contribute to the elucidation of biological markers for risk for BD in an integrative model.

show abstract

Section: Resultsmentioning

confidence: 99%

Neurobiology of Risk for Bipolar Disorder

Özerdem

Ceylan

Can

2016

Curr Treat Options Psych

View full text Add to dashboard Cite

show abstract

“…Many studies have addressed the clinical importance of BDNF in psychiatric diseases, and significant changes of the plasma BDNF levels for each condition have been demonstrated; 35 36 37 38 furthermore, some of the researchers also reported the recovery of lowered plasma BDNF levels, especially for depressive disorders, after proper treatment. 39 40 41 For somatization, however, investigation results regarding the implications of BDNF are extremely rare.…”

Section: Discussionmentioning

confidence: 99%

Decreased Plasma BDNF Levels of Patients with Somatization Disorder

Kang

Park

Kim

et al. 2016

Psychiatry Investig

View full text Add to dashboard Cite

ObjectiveBrain-derived neurotrophic factor (BDNF), one of the most abundant and important neurotrophins, is known to be involved in the development, survival, maintenance, and plasticity of neurons in the nervous system. Some studies have suggested that BDNF may play a role in the pathophysiology of several psychiatric illnesses such as depression and schizophrenia. Similarly, it is likely that the alteration of BDNF may be associated with the neuro-modulation that contributes to the development of somatization disorder.MethodsThe purpose of this study was to determine whether there is an abnormality of plasma BDNF levels in patients with somatization disorder, and to analyze the nature of the alteration after pharmacotherapy using an enzyme-linked immunosorbent assay (ELISA).ResultsThe plasma BDNF levels of the patients with a somatization disorder were significantly lower compared with those of the control volunteers (83.61±89.97 pg/mL vs. 771.36±562.14 pg/mL); moreover, the plasma BDNF levels of those patients who received an antidepressant were significantly increased after the treatment (118.13±91.45 pg/mL vs. 72.92±88.21 pg/mL).ConclusionThese results suggest that BDNF may play a role in the pathophysiology of somatization disorder.

show abstract

“…The Baron and Kenny approach was selected because it is a well-established approach to mediation analysis and has been used across a number of recent studies within the psychiatric literature (du Prel et al, 2014; Montemagni et al, 2014; Pagani et al, 2014; Parveen et al, 2014; Wicke et al, 2014; Yiaslas et al, 2014; du Prel and Peter, 2015; Park et al, 2015; Soltero et al, 2015; Yoshikawa et al, 2015; Barbui et al, 2016; Barth et al, 2016; Lepnurm et al, 2016; Oh and Kim, 2016). This approach tests the zero-order relationships between the independent variable (IV), depression, the dependent variable (DV), serum LDL changes, and the potential mediators (M).…”

Section: Methodsmentioning

confidence: 99%

Serum lipid changes following the onset of depressive symptoms in postmenopausal women

Persons

Robinson

Payne

et al. 2017

Psychiatry Research

View full text Add to dashboard Cite

A cross-sectional association between depression and serum low-density lipoprotein cholesterol (LDL-c) has been noted in psychiatric literature, raising the question of temporality: does low LDL-c predict depression, does depression lead to changes in LDL-c levels, or is this relationship bidirectional? In a previous longitudinal analysis of postmenopausal women ages 50–79 who participated in the Women’s Health Initiative (WHI), we detected an association between low LDL-c and the subsequent onset of depressive symptoms (HR=1.25, 95% CI 1.05–1.49, p=0.01). This current study uses the WHI cohort to explore the question of temporality in the opposite direction, examining the influence of depressive symptoms on subsequent changes in LDL-c levels. This study provides no evidence to suggest an association between depression and subsequent changes in LDL-c level (−2.78 mg/dL, 95% CI= −7.49 to 1.92, p=0.25), nor was any association detected for total cholesterol, HDL, or triglyceride changes over time. Further, this study demonstrates that the relationship between depression and serum LDL changes is not mediated by changes in weight, exercise, or energy intake.

show abstract

Preliminary study of anxiety symptoms, family dysfunction, and the brain-derived neurotrophic factor (BDNF) Val66Met genotype in offspring of parents with bipolar disorder

Cited by 21 publications

References 81 publications

Neurobiology of Risk for Bipolar Disorder

Neurobiology of Risk for Bipolar Disorder

Decreased Plasma BDNF Levels of Patients with Somatization Disorder

Serum lipid changes following the onset of depressive symptoms in postmenopausal women

Contact Info

Product

Resources

About